L-NAME iontophoresis: A tool to assess NO-mediated vasoreactivity during thermal hyperemic vasodilation in humans

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 5, 2013, Pages 361-368

  Dreyfuss, Céline ^a   Wauters, Aurélien ^a   Adamopoulos, Dionysios ^a   Pochet, Stéphanie ^b   Azarkan, Mohamed ^b   Berkenboom, Guy ^a,b   Van De Borne, Philippe ^a   Argacha, Jean François ^a  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE SODIUM; SODIUM CHLORIDE;

ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CORRELATION COEFFICIENT; FUNCTION TEST; HEATING; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; IONTOPHORESIS; LASER DOPPLER FLOWMETRY; PRIORITY JOURNAL; REPRODUCIBILITY; SKIN BLOOD VESSEL; SKIN IONTOPHORESIS; SKIN THERMAL HYPEREMIC TEST; SMOKING; VASODILATATION;

ADULT; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEASIBILITY STUDIES; HUMANS; HYPEREMIA; HYPERTHERMIA, INDUCED; INJECTIONS, INTRADERMAL; IONTOPHORESIS; LASER-DOPPLER FLOWMETRY; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROPRUSSIDE; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; SKIN; SMOKING; VASODILATION; YOUNG ADULT;

EID: 84877633378     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182858f81     Document Type: Article

References (49)

1. Vartiainen E, Puska P, Pekkanen J, et al. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. BMJ. 1994; 309:23-27.
2. Argacha JF, Adamopoulos D, Gujic M, et al. Acute effects of passive smoking on peripheral vascular function. Hypertension. 2008;51: 1506-1511.
3. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356: 2388-2398.
4. Giannarelli C, De Negri F, Virdis A, et al. Nitric oxide modulates tissue plasminogen activator release in normotensive subjects and hypertensive patients. Hypertension. 2007;49:878-884.
5. Targonski PV, Bonetti PO, Pumper GM, et al. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation. 2003;107:2805-2809.
6. Celermajer DS, Adams MR, Clarkson P, et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med. 1996;334:150-154.
7. Kalay N, Yarlioglues M, Ardic I, et al. The assessment of atherosclerosis on vascular structures in patients with acute coronary syndrome. Clin Invest Med. 2010;33:E36-E43.
8. Bots ML, Westerink J, Rabelink TJ, et al. Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: Effects of technical aspects of the FMD measurement on the FMD response. Eur Heart J. 2005;26: 363-368.
9. Sejda T, Pit'ha J, Svandová E, et al. Limitations of non-invasive endothelial function assessment by brachial artery flow-mediated dilatation. Clin Physiol Funct Imaging. 2005;25:58-61.
10. Debbabi H, Bonnin P, Ducluzeau PH, et al. Noninvasive assessment of endothelial function in the skin microcirculation. Am J Hypertens. 2010; 23:541-546.
11. Cracowski J-L, Minson CT, Salvat-Melis M, et al. Methodological issues in the assessment of skin microvascular endothelial function in humans. Trends Pharmacol Sci. 2006;27:503-508.
12. Turner J, Belch JJF, Khan F. Current concepts in assessment of microvascular endothelial function using laser Doppler imaging and iontophoresis. Trends Cardiovasc Med. 2008;18:109-116.
13. Farkas K, Kolossváry E, Járai Z, et al. Non-invasive assessment of microvascular endothelial function by laser Doppler flowmetry in patients with essential hypertension. Atherosclerosis. 2004;173:97-102.
14. Jadhav ST, Ferrell WR, Petrie JR, et al. Microvascular function, metabolic syndrome, and novel risk factor status in women with cardiac syndrome X. Am J Cardiol. 2006;97:1727-1731.
15. de Jongh RT, Serné EH, IJzerman RG, et al. Microvascular function: A potential link between salt sensitivity, insulin resistance and hypertension. J Hypertens. 2007;25:1887-1893.
16. Clough GF. Role of nitric oxide in the regulation of microvascular perfusion in human skin in vivo. J Physiol. 1999;516(Pt 2):549-557.
17. Mathew V, Cannan CR, Miller VM, et al. Enhanced endothelinmediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. Circulation. 1997;96: 1930-1936.
18. Pritchard KA, Groszek L, Smalley DM, et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res. 1995;77:510-518.
19. Kellogg DL, Liu Y, Kosiba IF, et al. Role of nitric oxide in the vascular effects of local warming of the skin in humans. J Appl Physiol. 1999;86: 1185-1190.
20. van der Linde NAJ, Boomsma F, van den Meiracker AH. Role of nitric oxide in modulating systemic pressor responses to different vasoconstrictors in man. J Hypertens. 2005;23:1009-1015.
21. Ferrell WR, Ramsay JE, Brooks N, et al. Elimination of electrically induced iontophoretic artefacts: Implications for non-invasive assessment of peripheral microvascular function. J Vasc Res. 39:447-455.
22. Goldsmith PC, Leslie TA, Hayes NA, et al. Inhibitors of nitric oxide synthase in human skin. J Invest Dermatol. 1996;106:113-118.
23. Bircher A, de Boer EM, Agner T, et al. Guidelines for measurement of cutaneous blood flow by laser Doppler flowmetry. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis. 1994;30:65-72.
24. Kim JH, Bugaj LJ, Oh YJ, et al. Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. J Appl Physiol. 2009;107:1249-1257.
25. Yang Y-M, Huang A, Kaley G, et al. eNOS uncoupling and endothelial dysfunction in aged vessels. Am J Physiol Heart Circ Physiol. 2009;297: H1829-H1836.
26. Sokolnicki LA, Strom NA, Roberts SK, et al. Skin blood flow and nitric oxide during body heating in type 2 diabetes mellitus. J Appl Physiol. 2009;106:566-570.
27. Boushel R, Langberg H, Gemmer C, et al. Combined inhibition of nitric oxide and prostaglandins reduces human skeletal muscle blood flow during exercise. J Physiol. 2002;543(Pt 2):691-698.
28. Schrage WG, Joyner MJ, Dinenno FA. Local inhibition of nitric oxide and prostaglandins independently reduces forearm exercise hyperaemia in humans. J Physiol. 2004;557(Pt 2):599-611.
29. Kellogg DL. In vivo mechanisms of cutaneous vasodilation and vasoconstriction in humans during thermoregulatory challenges. Appl Physiol. 2006;100:1709-1718.
30. Kellogg DL, Zhao JL, Wu Y, et al. Antagonism of soluble guanylyl cyclase attenuates cutaneous vasodilation during whole body heat stress and local warming in humans. J Appl Physiol. 2011;110:1406-1413.
31. Nakayama M, Yasue H, Yoshimura M, et al. T(-786)-. C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis. Am J Cardiol. 2000;86:628-634.
32. Anderson C, Andersson T, Wårdell K. Changes in skin circulation after insertion of a microdialysis probe visualized by laser Doppler perfusion imaging. J Invest Dermatol. 1994;102:807-811.
33. Cracowski J-L, Lorenzo S, Minson CT. Effects of local anaesthesia on subdermal needle insertion pain and subsequent tests of microvascular function in human. Eur J Pharmacol. 2007;559:150-154.
34. Hodges GJ, Chiu C, Kosiba WA, et al. The effect of microdialysis needle trauma on cutaneous vascular responses in humans. J Appl Physiol. 2009; 106:1112-1118.
35. MedowMS,Minson CT, Stewart JM. Decreased microvascular nitric oxidedependent vasodilation in postural tachycardia syndrome. Circulation. 2005; 112:2611-2618.
36. Sacerdoti D, Mania D, Pesce P, et al. Role of HO/CO in the control of peripheral circulation in humans. Int J Hypertens. 2012;2012:236180.
37. Raitakari OT, Celermajer DS. Flow-mediated dilatation. Br J Clin Pharmacol. 2000;50:397-404.
38. Widlansky ME, Gokce N, Keaney JF, et al. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42:1149-1160.
39. Ozaki K, Hori T, Ishibashi T, et al. Effects of chronic cigarette smoking on endothelial function in young men. J Cardiol. 2010;56:307-313.
40. Talukder MAH, Johnson WM, Varadharaj S, et al. Chronic cigarette smoking causes hypertension, increased oxidative stress, impaired NO bioavailability, endothelial dysfunction, and cardiac remodeling in mice. Am J Physiol Heart Circ Physiol. 2011;300:H388-H396.
41. Argacha JF, Adamopoulos D, Dreyfuss C, et al. Effect of cigarette smoke on oxidative stress and vascular endothelial function. In: Matata B, Elahi M, eds. Oxidative Stress: A Focus on Cardiovascular Disease Pathogenesis. New York: Nova Science Publishers, Inc. 2010:235-256.
42. Node K, Kitakaze M, Yoshikawa H, et al. Reversible reduction in plasma concentration of nitric oxide induced by cigarette smoking in young adults. Am J Cardiol. 1997;79:1538-1541.
43. Wright JL, Dai J, Zay K, et al. Effects of cigarette smoke on nitric oxide synthase expression in the rat lung. Lab Invest. 1999;79:975-983.
44. Zou YY, Lu J, Poon DJ, et al. Combustion smoke exposure induces up-regulated expression of vascular endothelial growth factor, aquaporin 4, nitric oxide synthases and vascular permeability in the retina of adult rats. Neuroscience. 2009;160:698-709.
45. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: An update. J Am Coll Cardiol. 2004;43:1731-1737.
46. Pellaton C, Kubli S, Feihl F, et al. Blunted vasodilatory responses in the cutaneous microcirculation of cigarette smokers. Am Heart J. 2002;144: 269-274.
47. Rahman MM, Laher I. Structural and functional alteration of blood vessels caused by cigarette smoking: An overview of molecular mechanisms. Curr Vasc Pharmacol. 2007;5:276-292.
48. Armani C, Landini L, Leone A. Interactive effect of cigarette smoking and gene variants for predisposing to cardiovascular disease. Curr Pharm Des. 2010;16:2531-2538.
49. Augustyniak RA, Thomas GD, Victor RG, et al. Nitric oxide pathway as new drug targets for refractory hypertension. Current Pharm Des. 2005; 11:3307-3315.